GLG News by Medical Device Experts

From the day that Charnley first developed the artificial hip, there has never been a question that eventually revisions would become a larger market than primary hips and knees.  Joint reconstruction with metal and plastics was never intended, even with today's technology, would be consider...

The recent publication of new cases of pancreatitis that are occurring in patients taking Byetta (exenatide) can't be good for Amylin/Lilly. While Byetta and investigational GLP-1 analogs are still very viable therapeutics for Type 2 Diabetes, prescribers will have to reassess the risk-benefit ratio...

1)  Concerns over the new FDA restrictions on ESA's is being overstated. 2)  Amgen will continue to do well in the ESA market place, in spite of these changes. 3)  J&J will receive the brunt of these changes, strictly because of their market concentration in the oncology market. 4) ...

The VA has already won many awards for an electronic medical records system, which tax payers have already paid for. Adopting the VA "CPRS" program would save the taxpayers and the private sector hundreds of billions of dollars.

Product liability exposure of new materials makers can be severe, especially with fatal consequences of failures Internal memos re product problems can shoot company in the foot; prudent firms have a plan for controlling open-ended speculative memos in an instant-message environment Major PR and govt....

First, and foremost, the only working link for this article can be found at: http://www.reuters.com/article/domesticNews/idUSWAT00934620080415?feedType=RSS&feedName=domesticNews Although there is no proof offered in the article to substantiate the suggestion of fraud, there is enough circumstantial...

One only has to read about the Heparin debacle, which has killed, at least, 81 Americans, to realize that there is a serious issue with the quality of medicines produced in China.  Manufacturing of medical food and consumer goods in China is growing at such a rate, the Chinese government has neither...

It's easy to point fingers of blame and this article does that, very well.  According to the "annalysis" everybody is to blame.  And, they're right, everyone is to blame, but where the article fails is the authoris inability to point out a real solution to the problem of wasted dollars spent...

Over the last year, it has become clear that the over-use of anemia drugs for cancer and renal failure has become a problem.  The reason can be sumed up in one word, which is profit.

Rexam's results show why successful healthcare packagers are often niche players. Healthcare packaging is a diverse field encompassing rigid containers in all shapes and sizes and unlimited varieties of flexible forms, materials and shapes. For large players supporting high speed capital intensive manufacturing...